ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming ConferencesUnternehmensmeldung28. Okt. 2026ENProQR Therapeutics N.V.Company announcement feed
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI AdvisorUnternehmensmeldung23. Sept. 2026ENProQR Therapeutics N.V.Company announcement feed
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026Unternehmensmeldung9. Sept. 2026ENProQR Therapeutics N.V.Company announcement feed
ProQR to Participate in Upcoming Investor Conferences in September 2026Unternehmensmeldung2. Sept. 2026ENProQR Therapeutics N.V.Company announcement feed
ProQR Announces Second Quarter 2026 Operating and Financial ResultsUnternehmensmeldung13. Aug. 2026ENProQR Therapeutics N.V.Company announcement feed
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing PlatformUnternehmensmeldung25. Juni 2026ENProQR Therapeutics N.V.Company announcement feed
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private PlacementUnternehmensmeldung25. Juni 2026ENProQR Therapeutics N.V.Company announcement feed
ProQR Announces First Quarter 2026 Operating and Financial ResultsUnternehmensmeldung12. Mai 2026ENProQR Therapeutics N.V.Company announcement feed
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing PlatformUnternehmensmeldung11. Mai 2026ENProQR Therapeutics N.V.Company announcement feed
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026Unternehmensmeldung4. Mai 2026ENProQR Therapeutics N.V.Company announcement feed
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of DirectorsUnternehmensmeldung30. Apr. 2026ENProQR Therapeutics N.V.Company announcement feed
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst EventUnternehmensmeldung8. Apr. 2026ENProQR Therapeutics N.V.Company announcement feed